The BNT162b2 mRNA COVID-19 vaccine is highly effective at generating immune responses in people over the age of 80 years and provides good cross neutralization of the P.1 gamma variant of concern.

Animal experiments show that the mosaic-type immunogen integrating key mutations from Omicron and other circulating variants elicits broad neutralization against divergent SARS-CoV-2 strains.

To quantify serum or antibody activity against HIV-1, logistic regression of single-dilution neutralization outcomes can efficiently summarize neutralization potency and indicate which samples may lack sufficient statistical support, for high-throughput screening in large-scale vaccine trials.

A large repertoire of nanobodies that target discrete regions of SARS-CoV-2 spike shows effective neutralization against variants of concern with many pairwise combinations resistant to escape and demonstrating synergistic neutralization activities.

Serum antibodies induced by CoronaVac tended to decrease over time, even though vaccinated with the homologous booster dose, and Delta and Omicron variants may be able to more efficiently evade the antibodies with time.

A novel antibody recognizing receptor-binding region of MARV glycoprotein was developed and displays broad-spectrum neutralizing activity to filovirus species when NPC2 was fused to the N-terminus of the mAb.

A combination of eight serological surveys shows a decline in seroprevalence over a two-year period following the first reports of Zika transmission in Fiji and French Polynesia.

A model-based approach for modelling the immune control of viral dynamics is applied to quantify the effect of several SARS-CoV-2 vaccine platforms and to define mechanistic correlates of protection.

Extended somatic hypermutation and clonal evolution associated with antibody neutralization breath in HIV controllers with low plasma viral loads provide promise for HIV vaccine development.

Despite the virus' error prone polymerase, influenza virus antigenic evolution is rare, even in previously immune hosts, virus replication occurs before producing new antibodies.